Acute hepatotoxicity caused by repaglinide [4]

Annals of Internal Medicine

Volumn 141, Issue 10, 2004, Pages 823-

  Nan, Daniel N ^a   Hernández, José L ^a   Fernández Ayala, Marta ^b   Carrascosa, Miguel ^b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL DE LAREDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

REPAGLINIDE;

ACUTE DISEASE; AGED; CASE REPORT; CHOLESTASIS; DIARRHEA; DRUG HYPERSENSITIVITY; DYSPEPSIA; EOSINOPHILIA; FEVER; HEADACHE; HEPATITIS; HUMAN; HYPERGLYCEMIA; LETTER; LIVER TOXICITY; MALE; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; VOMITING;

EID: 8744267245     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-141-10-200411160-00024     Document Type: Letter

References (5)

1. Owens DR. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. Eur J Clin Invest. 1999;29 Suppl 2:30-7. [PMID: 10383608]
2. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61:1625-60. [PMID: 11577798]
3. Sherlock S. The spectrum of hepatotoxicity due to drugs. Lancet. 1986;2:440-4. [PMID: 2874423]
4. Kaplowitz N, Aw TY, Simon FR, Stolz A. Drug-induced hepatotoxicity. Ann Intern Med. 1986;104:826-39. [PMID: 3518564]
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45. [PMID: 7249508]